ImmunityBio Inc

NASDAQ:IBRX  
9.31
-0.27 (-2.82%)
Mergers / Acquisitions

National Cancer Institute Selects Immunitybio’S N-803 Il-15 Receptor Agonist To Combine With Keytruda In 700-Site Lung-Map Clinical Trial Of A Chemo-Free Therapy

Published: 10/04/2021 12:47 GMT
ImmunityBio Inc (IBRX) - National Cancer Institute Selects Immunitybio’s N-803 Il-15 Receptor Agonist to Combine With Keytruda in 700-site Lung-map Clinical Trial of a Chemo-free Therapy.
Immunitybio Inc - Enrollment is Anticipated to Begin in Q4 2021.